Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivity
June 8, 2017 | Press Releases
PCCTC study serves as the foundation for a therapeutically relevant classification of prostate cancer.
Committed to world-class science!
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.